Colorectal Cancers, Small Bowel Cancers
Conditions
Keywords
CEA MUC1 Vaccine, CV301, M7824, N-803, NHS-IL12, Bintrafusp alfa, M9241
Brief summary
Background: Metastatic or refractory/recurrent small bowel and colorectal cancers cannot be cured and are often not helped by standard treatments. Researchers want to find better treatments by testing a combination of drugs. Objective: To learn if a new combination of immunotherapy drugs can shrink tumors in people with advanced small bowel and colorectal cancers. Eligibility: People ages 18 and older who have advanced metastatic or refractory/recurrent small bowel and/or colorectal cancer. Design: Participants will be screened on a separate protocol. They will have a physical exam and medical history. They will have imaging scans. They will have blood and urine tests. Their heart function will be measured. They may have a tumor biopsy. Participants will repeat some of the screening tests during the study. Participants will be put into study groups. Each group will get a combination of the following drugs: CV301 vaccine (modified vaccinia Ankara (MVA)-BN-CV301 and Fowlpox (FPV)-CV301), M7824 (MSB0011359C), and N-803 (Anktiva). Some will also get NHS-IL12 (M9241). Participants will get the CV301 vaccines by injection under the skin. They will get M7824 by intravenous infusion every 2 weeks. They will get N-803 by injection under the skin every 2 or 4 weeks. They may get NHS-IL12 by injection under the skin every 4 weeks. They will take the study drugs for up to 1 year. They will visit the National Institutes of Health (NIH) every 2 weeks. After treatment ends, participants will go to the clinic for a 28-day follow-up visit or have a telephone call. They will be contacted every 3 months for 1 year, and then every 6 months after that for the rest of their life.
Detailed description
Background: * Metastatic or refractory/recurrent small bowel and colorectal cancers are incurable and poorly palliated by standard therapies. There is an unmet need for active treatments for these tumors. * To date immunotherapies including anti programmed cell death protein 1 (PD-1) or anti programmed death-ligand 1 (PD-L1) inhibitors have proven largely ineffective for the vast majority of these cancers. * In microsatellite stable (MSS) colorectal cancer (\>95% of these cancers) the response rate to checkpoint inhibitors has been \<5%. * Preclinical studies suggest that the use of different combinations of multiple immunotherapy agents may improve anti-tumor efficacy. These studies have employed (1) a vaccine targeting a tumor associated antigen, (2) an IL-15 superagonist (N-803, also known as ALT-803), (3) an anti-PD-L1 MAb or a bifunctional fusion protein targeting PD-L1 and TGF beta (M7824 (MSB0011359C), and (4) a tumor targeted immunocytokine (NHS-IL12 (M9241). Objectives: To evaluate the objective response rate (ORR) according to Response Evaluation Criteria (Response Evaluation Criteria in Solid Tumors (RECIST) 1.1) of the combination of (1) CV301, a poxviral based vaccine targeting carcinoembryonic antigen (CEA) and mucin-1 (MUC1), (2) N-803 and (3) M7824; and of the combination of (1) CV301, (2) N-803, (3) M7824 and (4) NHS-IL12 (M9241) in subjects with advanced checkpoint naive microsatellite stable (MSS) small bowel and colorectal cancers. Eligibility: * Age \>= 18 years old * Subjects with cytologically or histologically confirmed locally advanced or metastatic small bowel or colorectal adenocarcinomas. * Prior first line systemic therapy is required unless the patient declines standard treatment after appropriate counseling has been provided. * Subjects must have measurable disease. Design: * This is a phase II trial of combination immunotherapy, with a brief dose escalation portion for Arm 2. * The trial will be conducted using a Simon optimal two-stage design in each Phase II Arm. * Patients will be enrolled on the following arms in sequential order: (1) Arm 1: CV301 + M7824 + N-803, (2) Arm 2A and Arm 2B: CV301 + M7824 + N-803 + NHS-IL12; N-803 dose level will be evaluated in Arm 2A prior to further enrollment in Arm 2B. * The first six patients on arm 1 will be evaluable for dose limiting toxicities (DLTs) and accrual will only continue to 9 patients on that arm if less than 2 out of the first 6 patients experience a DLT. * In Arm 2B, patients will receive 4 drug treatments (CV301 + M7824 + N-803 + NHSIL12), but the dose level of N-803 will first be determined during a 3-level dose escalation portion, Arm 2A. Following determination of the maximum tolerated dose (MTD) or highest safe dose evaluated, the 6 patients at that dose level will be included among the initial 9 patients for the first stage of that arm. * If two or more out of nine patients have objective responses on a given arm that arm will be expanded to enroll 20 evaluable patients.
Interventions
BIOLOGICALCV301
CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
DRUGMSB0011359C
Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
DRUGN-803
N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
DRUGNHS-IL12
NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-INCLUSION CRITERIA: 1. Subjects with cytologically or histologically confirmed locally advanced or metastatic small bowel or colorectal adenocarcinoma 2. Subjects must have received two prior lines of systemic therapy unless the subject is not eligible to receive standard therapy or declines standard treatment 3. Subjects must have measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performance status \<= 2 5. Adequate hematologic function at screening, as follows: * Absolute neutrophil count (ANC) \>=1 x 10\^9/L * Hemoglobin \>= 9 g/dL * Platelets \>= 75,000/microliter 6. Adequate renal and hepatic function at screening, as follows: \- Serum creatinine \<= 1.5 x upper limit of normal (ULN) OR Measured or calculated creatinine clearance \>= 40 mL/min for participant with creatinine levels \> 1.5 X institutional ULN (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl); * Bilirubin \<= 1.5 x ULN OR in subjects with Gilbert's syndrome, a total bilirubin \<= 3.0 x ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 2.5 x ULN, unless liver metastases are present, then values must be \<= 3 x ULN) 7. The effects of the immunotherapies on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment and up to two months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 8. Participants serologically positive for human immunodeficiency virus (HIV), Hep B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR). HIV positive participants must have cluster of differentiation 4 (CD4) count \>= 200 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy for at least 4 weeks and have no reported opportunistic infections or Castleman s disease within 12 months prior to enrollment. 9. Ability of subject to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. Participants with prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 28 days prior to the first drug administration except if the investigator has assessed that all residual treatment-related toxicities have resolved or are minimal and feel the participant is otherwise suitable for enrollment. Additionally, current therapies (e.g., maintenance capecitabine) may be continued where in the opinion of the investigator stopping such therapies may increase the risk of disease progression. Also, participants may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g., breast). 2. Participants with microsatellite unstable or mismatch repair deficient disease. 3. Major surgery within 28 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted). 4. Known life-threatening side effects resulting from prior checkpoint inhibitor therapy (e.g., colitis, pneumonitis, fulminant hepatitis which led to permanent discontinuation of prior checkpoint therapy). Autoimmune toxicity which was not life threatening (e.g., arthritis) or did not lead to discontinuation of prior checkpoint therapy is allowed. 5. Known active brain or central nervous system metastasis (less than a month out from definitive radiotherapy or surgery), seizures requiring anticonvulsant treatment (\<3 months) or clinically significant cerebrovascular accident (\<3 months). In order to be eligible participants must have repeat central nervous system (CNS) imaging at least a month after definitive treatment showing stable CNS disease. Participants with evidence of intra-tumoral or peritumoral hemorrhage on baseline imaging are also excluded unless the hemorrhage is grade \<= 1 and has been shown to be stable on two consecutive imaging scans. 6. Pregnant women are excluded from this study because these drugs have not been tested in pregnant women and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these immunotherapies, breastfeeding should be discontinued if the mother is treated on this protocol. 7. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent with exception of: * Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorders not requiring immunosuppressive treatment; * Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses \<= 10 mg of prednisone or equivalent per day; * Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable; * Subjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (\<= the equivalent of prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or cyclosporin A are excluded on the basis of potential immune suppression. For these subjects these excluded treatments must be discontinued at least 1 weeks prior to enrollment for recent short course use (\<= 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (\> 14 days). In addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study. 8. Subjects with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3 months) clinically significant bleeding events or other illness considered by the Investigator as high risk for investigational drug treatment. 9. Subjects unwilling to accept blood products as medically indicated. 10. History of second malignancy within 3 years of enrollment except for the following: adequately treated localized skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other localized malignancy which has been adequately treated or malignancy which does not require active systemic treatment (e.g., low risk chronic lymphocytic leukemia (CLL). 11. Subjects with a known severe hypersensitivity reaction to a monoclonal antibody (grade \>= 3 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE v5) will be evaluated by the allergy/immunology team prior to enrollment. 12. Receipt of any organ transplantation requiring ongoing immunosuppression. 13. Receipt of prior lymphodepleting chemotherapy (e.g., cyclophosphamide or fludarabine at standard lymphodepleting doses).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) for Quadruple Therapy | one year | ORR of the combination of (1) Carcinoembryonic antigen (CEA)/Mucin-1 (MUC1) vaccines, (2) N-803 (Anktiva), (3) M7824 (MSB0011359C) and (4) NHS-IL12 (M9241) in participants with advanced small bowel and colorectal cancers was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response is a complete or partial radiographic response as defined by RECIST 1.1. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. |
| Objective Response Rate (ORR) for Triple Therapy | one year | ORR of the combination of (1) Carcinoembryonic antigen (CEA)/Mucin-1 (MUC1) vaccines, (2) N-803 (Anktiva) and (3) M7824 (MSB0011359C) in participants with advanced small bowel and colorectal cancers was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response is a complete or partial radiographic response as defined by RECIST 1.1. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Date treatment consent signed to date off study, approximately 27 months for Cohort 2, Arm 2a Dose Level 1; 18 months and 29 days for cohort 2, Arm 2a Dose Level 2; and 7 months and 20 days for Cohort 2, Arm 2b, Dose Level 2. | Safety of the combination of (1) CV301, (2) N-803 (Anktiva), (3) M7824 (MSB0011359C) and (4) NHS-IL12 (M9241) in participants with advanced small bowel and colorectal cancers was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. |
| Progression Free Survival (PFS) | From time to enrollment up to 35 months | PFS per treatment assignment (three or four drug combination was evaluated using Kaplan-Meier methods and is defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Participants who do not have disease progression or have not died at the end of follow up will be censored at the last known date the participant was progression free. Progression was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
| Duration of Response (DOR) | Up to 34 months | DOR per treatment assignment (three or four drug combination) is measured from the time measurement criteria are met for Complete Response (CR) or Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. |
| Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD) | time participant is first enrolled to time participant is taken off of study treatment, an average of 2.1 months. | Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. And progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
| Overall Survival (OS) | Up to 35 months | OS per treatment assignment (three or four drug combination) evaluated using Kaplan-Meier methods. OS is defined as the time from the date of first treatment to the date of death (any cause). Participants who are alive at the end of follow up will be censored at the last known date alive. |
| Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Date treatment consent signed to date off study, approximately 29 months and 1 day for Cohort 1, Arm 1. | Safety of the combination of (1) CV301, (2) N-803 (Anktiva) and (3) M7824 (MSB0011359C) in participants with advanced small bowel and colorectal cancers was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | Date treatment consent signed to date off study, approximately 29 months and 1 day for Cohort 1, Arm 1; 27 months for Cohort 2, Arm 2a Dose Level (DL) 1; 18 months and 29 days for cohort 2, Arm 2a DL 2; and 7 months and 20 days for Cohort 2, Arm 2b, DL 2. | Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) Carcinoembryonic antigen (CEA)/ Mucin 1 (MUC1) Vaccines + (M7824 (MSB0011359C) + N-803 (Anktiva) (Triple Therapy).
CV301: CV301 vaccine consists of modified vaccinia Ankara (MVA)-BN-CV301 and Fowlpox (FPV)-CV301). MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous (SC) injections on Day (D)1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
MSB0011359C: Participants will receive M7824 via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
N-803: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B. | 12 |
| Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation Carcinoembryonic antigen (CEA)/ Mucin 1 (MUC1) Vaccines + M7824 (MSB0011359C) + N-803 (Anktiva) + (NHS-IL12 (M9241) (Quadruple Therapy); dose escalation of NHS-IL12.
CV301: CV301 vaccine consists of modified vaccinia Ankara (MVA)-BN-CV301 and Fowlpox (FPV)-CV301). MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous (SC) injections on Day (D1) and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
MSB0011359C: Participants will receive M7824 via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
N-803: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
NHS-IL12: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B. | 8 |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation Carcinoembryonic antigen (CEA)/Mucin-1 (MUC-1) Vaccines + M7824 (MSB0011359C) + N-803 (Anktiva) + NHS-IL12 (M9241) (Quadruple Therapy); dose escalation of NHS-IL12.
CV301: CV301 vaccine consists of modified vaccinia Ankara (MVA)-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous (SC) injections on Day (D)1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
MSB0011359C: Participants will receive M7824 via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
N-803: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
NHS-IL12: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B. | 6 |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose Carcinoembryonic antigen (CEA)/Mucin-1 (MUC-1) Vaccines + M7824 (MSB0011359C) + N-803 (Anktiva) + NHS-IL12 (M9241) (Quadruple Therapy); fixed dose of NHS-IL12.
CV301: CV301 vaccine consists of modified vaccinia Ankara (MVA)-BN-CV301 and Fowlpox (FPV)-CV301). MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous (SC) injections on Day (D)1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
MSB0011359C: Participants will receive M7824 via intravenous (IV) infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
N-803: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
NHS-IL12: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B. | 6 |
| Total | 32 |
Baseline characteristics
| Characteristic | Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation | Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 11 Participants | 6 Participants | 4 Participants | 5 Participants | 26 Participants |
| Age, Continuous | 55.27 years STANDARD_DEVIATION 8.31 | 56.64 years STANDARD_DEVIATION 13.82 | 50.72 years STANDARD_DEVIATION 16.47 | 58.85 years STANDARD_DEVIATION 5.7 | 55.43 years STANDARD_DEVIATION 11.12 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants | 8 Participants | 6 Participants | 6 Participants | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 1 Participants | 0 Participants | 0 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 6 Participants | 6 Participants | 6 Participants | 5 Participants | 23 Participants |
| Region of Enrollment United States | 12 participants | 8 participants | 6 participants | 6 participants | 32 participants |
| Sex: Female, Male Female | 8 Participants | 4 Participants | 1 Participants | 4 Participants | 17 Participants |
| Sex: Female, Male Male | 4 Participants | 4 Participants | 5 Participants | 2 Participants | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 9 / 12 | 5 / 8 | 4 / 6 | 3 / 6 |
| other Total, other adverse events | 12 / 12 | 8 / 8 | 6 / 6 | 6 / 6 |
| serious Total, serious adverse events | 2 / 12 | 4 / 8 | 1 / 6 | 0 / 6 |
Outcome results
Primary
Objective Response Rate (ORR) for Quadruple Therapy
ORR of the combination of (1) Carcinoembryonic antigen (CEA)/Mucin-1 (MUC1) vaccines, (2) N-803 (Anktiva), (3) M7824 (MSB0011359C) and (4) NHS-IL12 (M9241) in participants with advanced small bowel and colorectal cancers was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response is a complete or partial radiographic response as defined by RECIST 1.1. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: one year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Objective Response Rate (ORR) for Quadruple Therapy | Complete Response | 12.5 Percentage of participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Objective Response Rate (ORR) for Quadruple Therapy | Partial Response | 0 Percentage of participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Objective Response Rate (ORR) for Quadruple Therapy | Complete Response | 0 Percentage of participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Objective Response Rate (ORR) for Quadruple Therapy | Partial Response | 0 Percentage of participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Objective Response Rate (ORR) for Quadruple Therapy | Complete Response | 0 Percentage of participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Objective Response Rate (ORR) for Quadruple Therapy | Partial Response | 0 Percentage of participants |
Primary
Objective Response Rate (ORR) for Triple Therapy
ORR of the combination of (1) Carcinoembryonic antigen (CEA)/Mucin-1 (MUC1) vaccines, (2) N-803 (Anktiva) and (3) M7824 (MSB0011359C) in participants with advanced small bowel and colorectal cancers was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response is a complete or partial radiographic response as defined by RECIST 1.1. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: one year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Objective Response Rate (ORR) for Triple Therapy | Complete Response | 0 Proportion of participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Objective Response Rate (ORR) for Triple Therapy | Partial Response | 0 Proportion of participants |
Secondary
Duration of Response (DOR)
DOR per treatment assignment (three or four drug combination) is measured from the time measurement criteria are met for Complete Response (CR) or Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to 34 months
Population: 1/32 participants were evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Duration of Response (DOR) | 34 Months |
Secondary
Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD)
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. And progression was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: time participant is first enrolled to time participant is taken off of study treatment, an average of 2.1 months.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD) | 1 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD) | 1 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD) | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants Hospitalized Due to Serious Adverse Events Attributed to Progressive Disease (PD) | 0 Participants |
Secondary
Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy
Safety of the combination of (1) CV301, (2) N-803 (Anktiva), (3) M7824 (MSB0011359C) and (4) NHS-IL12 (M9241) in participants with advanced small bowel and colorectal cancers was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: Date treatment consent signed to date off study, approximately 27 months for Cohort 2, Arm 2a Dose Level 1; 18 months and 29 days for cohort 2, Arm 2a Dose Level 2; and 7 months and 20 days for Cohort 2, Arm 2b, Dose Level 2.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Anemia | 3 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 General disorders & administration site conditions - Mucosal bleeding, lower GI hemorrhage | 0 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Adrenal insufficiency | 0 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 5 | 0 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 4 | 0 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Duodenal hemorrhage | 1 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Adrenal insufficiency | 1 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Anemia | 1 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Duodenal hemorrhage | 0 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 5 | 0 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 General disorders & administration site conditions - Mucosal bleeding, lower GI hemorrhage | 1 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 4 | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 4 | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 General disorders & administration site conditions - Mucosal bleeding, lower GI hemorrhage | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Anemia | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 5 | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Adrenal insufficiency | 0 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Quadruple Therapy | Grade 3 Duodenal hemorrhage | 0 Participants |
Secondary
Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy
Safety of the combination of (1) CV301, (2) N-803 (Anktiva) and (3) M7824 (MSB0011359C) in participants with advanced small bowel and colorectal cancers was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: Date treatment consent signed to date off study, approximately 29 months and 1 day for Cohort 1, Arm 1.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 3 Alkaline phosphatase increased | 1 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 3 Anemia | 1 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 3 Aspartate aminotransferase increased | 1 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 3 Cardiac troponin I increased | 1 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 4 | 0 Participants |
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Grade 3, Grade 4, and/or Grade 5 Adverse Events Related to Triple Therapy | Grade 5 | 0 Participants |
Secondary
Overall Survival (OS)
OS per treatment assignment (three or four drug combination) evaluated using Kaplan-Meier methods. OS is defined as the time from the date of first treatment to the date of death (any cause). Participants who are alive at the end of follow up will be censored at the last known date alive.
Time frame: Up to 35 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Overall Survival (OS) | 19 Months |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Overall Survival (OS) | 19 Months |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Overall Survival (OS) | 4.5 Months |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Overall Survival (OS) | 7.0 Months |
Secondary
Progression Free Survival (PFS)
PFS per treatment assignment (three or four drug combination was evaluated using Kaplan-Meier methods and is defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. Participants who do not have disease progression or have not died at the end of follow up will be censored at the last known date the participant was progression free. Progression was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: From time to enrollment up to 35 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Progression Free Survival (PFS) | 1.8 Months |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Progression Free Survival (PFS) | 1.8 Months |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Progression Free Survival (PFS) | 1.8 Months |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Progression Free Survival (PFS) | 0.92 Months |
Other Pre-specified
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 29 months and 1 day for Cohort 1, Arm 1; 27 months for Cohort 2, Arm 2a Dose Level (DL) 1; 18 months and 29 days for cohort 2, Arm 2a DL 2; and 7 months and 20 days for Cohort 2, Arm 2b, DL 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241) | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 12 Participants |
| Cohort 2, Arm 2a, Dose Level (DL) DL2, Quad Therapy Dose Escalation | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 8 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 6 Participants |
| Cohort 2, Arm 2b Dose Level (DL)2, Quad Therapy Fixed Dose | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 6 Participants |